Biosimilars were introduced with the promise of expanding access to biologic therapies while reducing healthcare costs. As more blockbuster biologics lose exclusivity, biosimilars are becoming an incr...
Takeaways: Empaveli’s C3G/IC‑MPGN nod makes Sobi/Apellis the first movers in complement‑mediated kidney disease in Canada, turning a ~700‑patient ultra‑rare population into a high‑value, pr...
Takeaways: Apotex’s Denoza biosimilar gives Canada a home‑grown denosumab option, intensifying price and tender pressure on Amgen’s Prolia in a market with 2.3M osteoporosis ...
Takeaways: Health Canada’s CTA clearance positions Affinia among the first wave of next‑gen cardiac gene therapy players, using a bespoke AAV capsid to go after genetically defined BAG...
For decades, women’s health remained one of the most underfunded and underserved areas in healthcare despite representing half the global population. Many conditions affecting women received limited r...
Takeaways: This tie-up effectively turns WELL’s cardiologist network into an on‑demand, paid “virtual read” service layered on top of AliveCor’s at‑home ECG hardware and AI, direc...
Contract development and manufacturing organizations, often referred to as CDMOs, were once viewed primarily as outsourced service providers supporting pharmaceutical production. Today, their role is ...
Takeaways: CLOBIVIS modestly strengthens Apotex’s position in Canada’s post‑cataract segment and helps it move up the value chain in eye care beyond pure generics. In marke...
As the pharmaceutical industry becomes increasingly digital, cybersecurity is emerging as one of the sector’s most urgent and underestimated risks. Clinical trials, manufacturing operations, supply ch...
In-depth conversations with the executives, scientists, regulators, and innovators driving Canada’s pharmaceutical and life sciences landscape forward. Every policy decision, every drug approval...